Medical Updates

Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme. Gabrielle’s Angels supported this work with a grant to […]

Congratulations to Gabrielle’s Angel Foundation grantee Dr. Shan Zha for being elected to the American Society for Clinical Investigation. “Shan’s work is simply inspiring and is transforming the understanding of DNA repair and how we might utilize that understanding to develop new therapies,” says Jordan Orange, MD, PhD, the Reuben S. Carpentier Professor of Pediatrics and chair of the […]

Gabrielle’s Angels grantee Dr. Ari Melnick of Weill Cornell and his team have recently discovered that aggressive and relatively common lymphomas called diffuse large B cell lymphomas have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves. This is a huge breakthrough with many possibilities for future therapeutic applications!  […]

An immunotherapy harnessing the immune system’s “natural killer” cells has proven effective in treating acute myeloid leukemia (AML) in some adults whose cancers return. Now, researchers at Washington University School of Medicine in St. Louis have shown, in a small clinical trial, that the same natural killer cells also can help some children and young […]

Clockwise from top left: Andrew Intlekofer, MSKCC; Shannon Elf*, University of Chicago, Nathan Singh, Washington University St. Louis; Yibin Yang*, Fox Chase Cancer Center; Brian Dalton, Johns Hopkins University; Jamie Berta Spangler; Johns Hopkins University *Mark Foundation for Cancer Research Fellows – these grants will be fully funded by the Mark Foundation The Foundation’s Medical […]

A new study from the lab of longtime Gabrielle’s Angel Foundation Medical Advisory Board member Dr. John DiPersio and Gabrielle’s Angels grantee Dr. Stephen Persaud has revealed a new technique that may lead to safer stem cell transplants. The researchers at Washington University School of Medicine in St. Louis have developed a method of stem […]

Congratulations to Gabrielle’s Angels grantee Dr. Cigall Kadoch from Dana-Farber Cancer Institute for receiving the incredibly prestigious Howard Hughes Medical Institute (HHMI) Investigators Award! Dr. Kadoch will receive roughly $9 million over a seven-year term, which is renewable pending a successful scientific review. HHMI selected the new Investigators from more than 800 eligible applicants. To […]

The Mark Foundation for Cancer Research has partnered with the Gabrielle’s Angel Foundation for Cancer Research to fully support two of its Medical Research Awardees. The awardees, Dr. Shannon Elf from the University of Chicago, and Dr. Yibin Yang from Fox Chase Cancer Center were announced at the Angel Foundation’s 25th Angel Ball on August […]

Big news from the lab of former Gabrielle’s Angels grantee Dr. Scott Armstrong and his colleagues at Dana Farber! A new drug that not only could treat acute myeloid leukemia but also potentially prevent the cancer from developing is now being evaluated in clinical trials. This drug, SNDX-5613, successfully reversed leukemia development in mice and […]

We love this feature on one of our fabulous grantees, Dr. Esther Obeng of St. Jude! Not only is Dr. Obeng a first-generation American, she’s also designing studies to identify cancer-causing mutations and then developing clinical trials with revolutionary therapies that target them. “One of the reasons that I study the research that I do […]

Scientists have revealed how to modify CRISPR’s basic architecture to extend its reach beyond the genome and into the epigenome – proteins and small molecules that latch onto DNA and control when and where genes are switched on or off. Researchers at University of California San Francisco (UCSF) and the Whitehead Institute, both US, developed the […]

When researchers from Penn Medicine (including two of our grantees, Dr. Saar Gill and Dr. Marco Ruella!) found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn’t respond, they went back to the drawing board to determine why. They […]